Cedric Francois Sells 6,007 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Cedric Francois sold 6,007 shares of Apellis Pharmaceuticals stock in a transaction on Friday, January 17th. The shares were sold at an average price of $29.96, for a total transaction of $179,969.72. Following the completion of the sale, the chief executive officer now owns 301,408 shares in the company, valued at approximately $9,030,183.68. This represents a 1.95 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Cedric Francois also recently made the following trade(s):

• On Monday, January 13th, Cedric Francois sold 6,247 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $28.70, for a total value of $179,288.90.

Apellis Pharmaceuticals Stock Up 0.6 %

NASDAQ APLS traded up $0.19 on Tuesday, reaching $30.13. 1,461,289 shares of the stock traded hands, compared to its average volume of 2,274,031. Apellis Pharmaceuticals, Inc. has a 12 month low of $24.34 and a 12 month high of $71.90. The company has a market cap of $3.75 billion, a price-to-earnings ratio of -14.84 and a beta of 0.94. The company has a fifty day moving average price of $31.89 and a 200-day moving average price of $33.31. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The firm had revenue of $196.83 million during the quarter, compared to the consensus estimate of $200.00 million. During the same quarter in the previous year, the firm earned ($1.17) earnings per share. The business’s revenue was up 78.3% compared to the same quarter last year. As a group, research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.71 EPS for the current fiscal year.

Analyst Ratings Changes

APLS has been the subject of a number of recent research reports. Oppenheimer cut their target price on shares of Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. Robert W. Baird reduced their target price on shares of Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. Morgan Stanley initiated coverage on shares of Apellis Pharmaceuticals in a report on Thursday, November 21st. They issued an “equal weight” rating and a $31.00 price target for the company. Wells Fargo & Company reduced their price objective on Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 6th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and issued a $26.00 target price on shares of Apellis Pharmaceuticals in a report on Tuesday. Eight research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Apellis Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $46.71.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Several hedge funds have recently modified their holdings of APLS. Wolverine Asset Management LLC purchased a new stake in shares of Apellis Pharmaceuticals during the third quarter valued at about $27,000. True Wealth Design LLC purchased a new stake in Apellis Pharmaceuticals during the third quarter valued at approximately $27,000. Capital Performance Advisors LLP purchased a new position in Apellis Pharmaceuticals during the 3rd quarter worth $56,000. KBC Group NV increased its position in Apellis Pharmaceuticals by 34.8% during the 3rd quarter. KBC Group NV now owns 2,632 shares of the company’s stock valued at $76,000 after buying an additional 679 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in Apellis Pharmaceuticals by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock valued at $130,000 after buying an additional 781 shares during the last quarter. Hedge funds and other institutional investors own 96.29% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).